Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta [Neorecormon] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| epoetin beta [NeoRecormon] | Drug | As prescribed by physician |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life assessment: Kidney Disease Quality of Life Questionnaire | Throughout study: 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of factors (demographic and social characteristics, dialysis method) influencing the quality of life | Throughout study: 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
This trial is being conducted in Morocco.
Not provided
Not provided
Not provided
Dialysis patients with end-stage kidney disease on treatment with epoetin beta [Neorecormon]
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Casablanca | 20000 | Morocco |
Not provided
| ID | Term |
|---|---|
| D000740 | Anemia |
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C103998 | epoetin beta |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided